According to an evaluation of long-term data by April Armstrong (@domucla.bsky.social), #deucravacitinib demonstrated a consistent safety profile and durable clinical response through 5 years for patients with moderate to severe #psoriasis. #PsO #Dermatology

www.docwirenews.com/post/deucrav...

🆕 Visual Abstract with Healio 🎨

#Deucravacitinib in Psoriatic Arthritis: POETYK PsA-2

🎲 Phase 3 RCT of Deucravacitinib vs PBO
💊 Deucravacitinib = oral, selective TYK2 inhibitor
🥇 1st FDA-approved TYK2i for PsA

Healio Article 🔗: vist.ly/5hps8

#RheumSky #DermSky #PsoriaticArthritis